Lyell Immunopharma, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Caribou Biosciences, Inc.

Janux Therapeutics, Inc.

Agenus, Inc.

UroGen Pharma Ltd.

Scholar Rock Holding Corp.

Edgewise Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Aerovate Therapeutics, Inc.

Lyell Immunopharma, Inc.

iTeos Therapeutics, Inc.

Nautilus Biotechnology, Inc.

Why is Lyell Immunopharma, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Lyell Immunopharma, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Lyell Immunopharma, Inc.

68.97%

0.41

1788.78%

S&P 500

16.12%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-74.94%

EBIT Growth (5y)

-0.79%

EBIT to Interest (avg)

-218.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

69.71%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.50

EV to EBIT

-0.89

EV to EBITDA

-0.96

EV to Capital Employed

9.93

EV to Sales

181.64

PEG Ratio

Dividend Yield

ROCE (Latest)

-1116.46%

ROE (Latest)

-54.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -80.99 %

OPERATING PROFIT(Q)

Highest at USD -36.28 MM

PRE-TAX PROFIT(Q)

Highest at USD -39.68 MM

NET PROFIT(Q)

Highest at USD -39.68 MM

EPS(Q)

Highest at USD -2.13

-13What is not working for the Company

NET SALES(HY)

At USD 0.02 MM has Grown at -51.06%

OPERATING CASH FLOW(Y)

Lowest at USD -165.02 MM

ROCE(HY)

Lowest at -75.75%

RAW MATERIAL COST(Y)

Grown by 24.46% (YoY

Here's what is working for Lyell Immunopharma, Inc.

Operating Profit

Highest at USD -36.28 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -39.68 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -39.68 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -2.13

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at -80.99 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Lyell Immunopharma, Inc.

Net Sales

At USD 0.02 MM has Grown at -51.06%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -165.02 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Raw Material Cost

Grown by 24.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales